Comparison Study of Electrocardiogram Indexes in Patients With Epilepsy, Patients With First Seizure and Normal Population

NCT ID: NCT06608784

Last Updated: 2024-09-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

70 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-03-21

Study Completion Date

2024-08-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

According to recent advances in epileptic heart and sudden unexplained death in epilepsy, in this study the investigators aimed to compare ECG findings in patients with epilepsy, patients who had experienced their first seizure and patients without history of seizure.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Patients With Epilepsy Patients With First Seizure Normal Population

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with epilepsy

Patients with epilepsy who experienced a recent generalized tonic-clonic seizure

Electrocardiography

Intervention Type DIAGNOSTIC_TEST

12-lead electrocardiography

Patients with first seizure

Patients who experienced a recent generalized tonic-clonic seizure without any previous history

Electrocardiography

Intervention Type DIAGNOSTIC_TEST

12-lead electrocardiography

Normal population

Participants without history of seizure or epilepsy

Electrocardiography

Intervention Type DIAGNOSTIC_TEST

12-lead electrocardiography

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Electrocardiography

12-lead electrocardiography

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* History of epilepsy for at least 2 years
* Taking antiseizure medications


\- Solid history of first seizure confirmed by a neurologist


\- No history of seizure

Exclusion Criteria

* History of known cardiac disease or medical condition precipitating cardiac disease
* Electrolyte imbalance Taking medications with significant effect on ECG indexes
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Mazandaran University of Medical Sciences

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Nasim Tabrizi

Associate Professor of Neurology

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Mazandaran University of Medical Sciences

Sari, Mazandaran, Iran

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Iran

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

15028

Identifier Type: OTHER

Identifier Source: secondary_id

15028

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.